| Literature DB >> 32594577 |
Xiumei Hu1,2, Taixue An1,2, Bo Situ1, Yuhai Hu3, Zihao Ou1, Qiang Li1,2, Xiaojing He1, Ye Zhang1, Peifu Tian3, Dehua Sun1, Yongyu Rui1, Qian Wang1, Dan Ding4, Lei Zheng1,2.
Abstract
BACKGROUND: The detection of serum antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is emerging as a new tool for the coronavirus disease 2019 (COVID-19) diagnosis. Since many coronaviruses are sensitive to heat, heating inactivation of samples at 56°C prior to testing is considered a possible method to reduce the risk of transmission, but the effect of heating on the measurement of SARS-CoV-2 antibodies is still unclear.Entities:
Keywords: COVID-19; SARS-CoV-2; antibodies; heat inactivation; immunoanalysis
Mesh:
Substances:
Year: 2020 PMID: 32594577 PMCID: PMC7361150 DOI: 10.1002/jcla.23411
Source DB: PubMed Journal: J Clin Lab Anal ISSN: 0887-8013 Impact factor: 2.352
Figure 1The changes in the IgM and IgG levels of the 34 serum samples from patients with COVID‐19 infections detected by AFIA before (blue dot) and after heat inactivation (red dot). Dash line indicates the cutoff value of the assay
The signal intensity of the IgM and IgG levels of the 34 serum samples from patients with COVID‐19 infections detected by AFIA before and after heat inactivation
| Patient ID | IgM | IgG | ||
|---|---|---|---|---|
| Before inactivation | After inactivation | Before inactivation | After inactivation | |
| P1 | 3.16 | 0.51 | 25.36 | 14.25 |
| P2 | 10.68 | 5.00 | 109.02 | 88.66 |
| P3 | 3.70 | 1.28 | 24.52 | 41.56 |
| P4 | 10.54 | 6.07 | 38.08 | 14.22 |
| P5 | 2.98 | 1.40 | 3.59 | 7.08 |
| P6 | 1.18 | 0.57 | 99.46 | 34.40 |
| P7 | 1.35 | 0.50 | 13.77 | 4.63 |
| P8 | 3.83 | 0.91 | 26.02 | 12.23 |
| P9 | 5.56 | 3.40 | 5.55 | 6.06 |
| P10 | 10.36 | 2.94 | 5.70 | 8.91 |
| P11 | 2.11 | 0.96 | 200.56 | 61.56 |
| P12 | 3.60 | 1.62 | 25.00 | 28.59 |
| P13 | 1.21 | 0.75 | 265.06 | 162.96 |
| P14 | 3.52 | 1.07 | 182.76 | 35.36 |
| P15 | 3.17 | 2.73 | 82.78 | 25.12 |
| P16 | 2.98 | 0.56 | 2.17 | 1.61 |
| P17 | 1.22 | 0.82 | 24.41 | 26.28 |
| P18 | 17.53 | 3.90 | 13.94 | 13.43 |
| P19 | 1.77 | 1.38 | 12.21 | 31.69 |
| P20 | 2.74 | 1.18 | 19.88 | 14.83 |
| P21 | 10.60 | 10.17 | 2.11 | 1.57 |
| P22 | 1.54 | 1.09 | 24.24 | 12.76 |
| P23 | 1.26 | 1.14 | 4.89 | 5.78 |
| P24 | 2.19 | 0.98 | 35.14 | 14.69 |
| P25 | 4.97 | 1.34 | 16.51 | 21.42 |
| P26 | 19.08 | 3.22 | 38.14 | 15.81 |
| P27 | 1.98 | 1.91 | 3.37 | 4.00 |
| P28 | 3.36 | 1.81 | 17.23 | 9.57 |
| P29 | 2.01 | 0.95 | 13.99 | 4.52 |
| P30 | 7.35 | 3.79 | 17.57 | 5.10 |
| P31 | 2.76 | 0.82 | 42.84 | 42.98 |
| P32 | 5.06 | 1.43 | 1.43 | 0.94 |
| P33 | 3.24 | 0.98 | 12.93 | 5.19 |
| P34 | 3.59 | 0.73 | 1.63 | 11.45 |
Figure 2The changes in the IgM and IgG levels of 9 serum samples from non–COVID‐19 group detected by AFIA before (blue dot) and after heat inactivation (red dot)
The signal intensity of the IgM and IgG levels of 9 serum samples from non–COVID‐19 group detected by AFIA before and after heat inactivation
| Patient ID | IgM | IgG | ||
|---|---|---|---|---|
| Before inactivation | After inactivation | Before inactivation | After inactivation | |
| N1 | 0.42 | 0.27 | 0.09 | 0.04 |
| N2 | 0.13 | 0.18 | 0.43 | 0.07 |
| N3 | 0.25 | 0.02 | 0.09 | 0.02 |
| N4 | 0.33 | 0.4 | 0.19 | 0.71 |
| N5 | 0.63 | 0.26 | 0.7 | 0.02 |
| N6 | 0.26 | 0.12 | 0.21 | 0.57 |
| N7 | 1.01 | 0.97 | 0.82 | 0.13 |
| N8 | 0.61 | 0.56 | 0.59 | 0.25 |
| N9 | 0.69 | 0.34 | 0.39 | 0.00 |